Novoprotein(SH:688137) Xin Lang Zheng Quan·2025-10-14 01:27Core Insights - The stock of Nearshore Protein experienced a decline of 1.46% on October 13, with a trading volume of 13.18 million yuan [1] - The company reported a net financing outflow of 2.93 million yuan on the same day, with total financing and securities lending balance at 69.15 million yuan [1] Financing and Trading Activity - On October 13, Nearshore Protein had a financing buy-in of 1.55 million yuan, while the current financing balance is 69.15 million yuan, accounting for 5.05% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low position [1] - There were no shares sold or repaid in the securities lending market on October 13, with the lending balance also at zero, suggesting a high position relative to the 90th percentile level over the past year [1] Company Overview - Nearshore Protein, established on September 7, 2009, and listed on September 29, 2022, is located in Suzhou, Jiangsu Province [1] - The company's main business includes the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with related technical services [1] - The revenue composition is as follows: target and factor proteins 58.04%, enzymes and reagents 25.63%, CRO services 11.87%, recombinant antibodies 2.67%, and others 1.79% [1] Financial Performance - For the period from January to June 2025, Nearshore Protein achieved a revenue of 72.09 million yuan, representing a year-on-year growth of 20.85%, while the net profit attributable to the parent company was -24.22 million yuan, a decrease of 172% year-on-year [2] - Since its A-share listing, the company has distributed a total of 70.18 million yuan in dividends [3] Shareholder Information - As of August 20, the number of shareholders for Nearshore Protein was 6,459, a decrease of 4.41% from the previous period, with an average of 5,058 circulating shares per person, an increase of 4.61% [2] - As of June 30, 2025, notable institutional shareholders include Huashang LeXiang Flexible Allocation Mixed A, which increased its holdings by 41,500 shares, and several new institutional shareholders have entered the top ten list [3]